Sera Prognostics, Inc. — Q3 2021 Form 10-Q
Reporting period: Three and nine months ended September 30, 2021. Unaudited results; comparisons are against the corresponding 2020 periods. Sera is a women’s health diagnostics company whose lead commercial product is the PreTRM blood test for preterm-birth risk.
Financial performance and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $23,000 | $5,000 | $56,000 | $19,000 |
| Operating expenses | $9.465 million | $4.649 million | $22.904 million | $13.236 million |
| Operating loss | $9.442 million | $4.644 million | $22.848 million | $13.217 million |
| Net loss | $9.859 million | $5.072 million | $22.525 million | $14.473 million |
| Net loss per share, basic and diluted | $0.39 | $3.30 | $2.32 | $9.46 |
| Cash used in operating activities | Not separately presented for Q3 | $22.484 million | $12.683 million |
Revenue remained immaterial relative to expenses; the filing reports no significant commercial product revenue or recurring licensing revenue. Q3 cost of revenue was $10,000 against $23,000 of revenue. Operating expenses rose substantially year over year, led by selling and marketing, general and administrative, and research and development spending. Per-share loss comparisons are affected by the IPO, preferred-stock conversion, and reverse split.
At September 30, 2021, cash and cash equivalents were $82.5 million and marketable securities were $67.5 million, approximately $150.0 million combined. Current assets were $122.3 million versus current liabilities of $3.5 million. Stockholders’ equity was $150.0 million. The company reported no outstanding debt; capital lease obligations totaled approximately $145,000. Management stated existing resources were expected to fund operations and capital expenditures for at least 12 months from the financial-statement issuance date.
Material changes and notable items
- Revenue increased by $18,000 in Q3 and $37,000 over nine months versus 2020, but remained very small.
- Nine-month operating expenses increased $9.7 million year over year; the company attributed increases to expanded commercial staffing and activity, clinical and laboratory work, and public-company costs.
- Net loss widened by $4.8 million in Q3 and $8.1 million for the nine-month period. Nine-month other income included a $1.05 million gain from forgiveness of the PPP loan.
- Financing materially strengthened liquidity: the company raised approximately $99.0 million net from Series E preferred stock and $66.6 million net in its July IPO. Preferred stock converted into Class A and Class B common stock upon the IPO.
- Nine-month investing cash outflow was $68.1 million, primarily purchases of marketable securities. Financing cash inflow was $159.6 million, partially offset by repayment of bank debt and a convertible note.
Outlook, commentary, and risks
No quantified revenue, earnings, or test-volume guidance was provided. Management expects significant operating losses and negative operating cash flows for the foreseeable future, driven by PreTRM commercialization, clinical studies, and research and development. The company plans to expand commercial efforts and continue pursuing payer contracts.
Anthem’s multi-year commercial collaboration provides for minimum test purchases and payments during each of the first three years, but the filing reports no material revenue or cash receipts under the agreement through September 30, 2021. The company expects to rely on a limited number of customers, particularly Anthem, as commercialization develops.
- Commercial adoption, reimbursement coverage and rates, and successful execution of the Anthem agreement are uncertain; failure to secure broader payer contracts could constrain revenue and funding.
- COVID-19 had delayed PRIME study enrollment and limited clinician access; the filing says the extent of future operational and development effects remained uncertain.
- The PreTRM test is marketed as a laboratory-developed test. Potential changes to FDA oversight or legislation governing such tests could increase costs or delay commercialization.
- Additional risks include clinical-study outcomes, competition, laboratory and supplier continuity, regulatory and billing compliance, and intellectual-property protection. No material litigation was reported.
- Pre-IPO lockups were expected to expire January 10, 2022, potentially making substantial additional shares eligible for sale; equity-plan share increases and outstanding options and warrants may also dilute holders.
Investor verification points
- Track PreTRM test volumes, realized revenue, payer reimbursement, and actual purchases and payments under the Anthem agreement.
- Review cash burn against the approximately $150.0 million cash-and-securities balance and management’s stated 12-month liquidity horizon.
- Assess whether rising commercial, clinical, and administrative spending converts into broader coverage, adoption, and sustainable revenue.
- Follow PRIME study progress and any COVID-19-related impacts on enrollment, timelines, or commercialization.
- Check post-lockup share sales, equity compensation and warrant dilution, and any developments in FDA or legislative oversight of laboratory-developed tests.